Related Experiment Video
Updated: Jul 11, 2026
10:07
Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
Published on: March 20, 2012
Teratogenicity of lamotrigine
Canadian Family Physician Medecin De Famille Canadien
|September 18, 2007
Summary
Lamotrigine monotherapy in pregnancy is generally not linked to major birth defects. However, higher doses may pose risks, and fetal safety requires further study, though it
Area of Science:
- Obstetrics and Gynecology
- Neurology
- Pharmacology
Background:
- Epilepsy management during pregnancy presents challenges.
- Antiepileptic drugs (AEDs) carry potential risks to fetal development.
- Lamotrigine is a commonly used AED for epilepsy monotherapy.
Purpose of the Study:
- To evaluate the safety of lamotrigine monotherapy during early pregnancy.
- To address concerns regarding potential teratogenic effects of lamotrigine on the fetus.
- To guide clinical decisions on continuing or switching AEDs in pregnant epilepsy patients.
Main Methods:
- Review of existing studies on lamotrigine monotherapy in pregnant women with epilepsy.
- Analysis of data regarding major malformations and specific birth defects.
- Assessment of dose-dependent risks associated with lamotrigine treatment.
Main Results:
- Most studies indicate lamotrigine monotherapy is not associated with an increased risk of major malformations.
- A potential increased risk for major malformations has been suggested with lamotrigine doses exceeding 200 mg/day.
- Lamotrigine has not been identified as a major human teratogen, but definitive safety is not yet established.
Conclusions:
- Lamotrigine monotherapy appears relatively safe in early pregnancy, with no clear association with major malformations in most studies.
- Caution is advised regarding higher lamotrigine doses (>200 mg/day) due to potential risks.
- Further research is needed to definitively confirm fetal safety, but lamotrigine is not considered a major teratogen.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...